DetailsCategory: DNA RNA and CellsPublished on Monday, 13 January 2020 16:23Hits: 275
mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases
mRNA-6981 encodes PD-L1 to treat autoimmune disease, initially to be developed in autoimmune hepatitis
Company to expand pipeline of innovative vaccines in the near term based on clinical success of infectious disease vaccine portfolio to date
CAMBRIDGE, MA, USA I January 12, 2020 I Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has entered a new autoimmune therapeutic area. Building on the clinical validation of systemic delivery of mRNA provided by data from its antibody against the chikungunya virus (mRNA-1944) program, this new therapeutic area will include autoimmune and inflammatory diseases. The Company also announced that it will expand its pipeline of innovative vaccines in the near term, following six positive Phase 1 clinical trial readouts from its infectious disease portfolio and the initiation of a Phase 2 study for its CMV vaccine (mRNA-1647).
Modernas pipeline is organized into six modalities based on similar mRNA technologies, delivery technologies and manufacturing processes. The Companys approach is to leverage early programs within a modality to generate clinical data and insights that reduce the technology risk of subsequent programs and accelerate the expansion of the pipeline in that modality. Todays announcement reflects the Companys belief that recent positive Phase 1 data from its infectious disease vaccine portfolio, including its complex CMV vaccine, and chikungunya antibody program have de-risked its prophylactic vaccines and systemic therapeutics modalities. As a result, Moderna intends to bring new development candidates forward within these two areas.
2019 was an inflection point for Moderna with significant clinical advances resulting from our investments in science and manufacturing capabilities. The positive Phase 1 results from our CMV vaccine and chikungunya antibody programs validate our approach and help clinically de-risk the delivery technologies for our prophylactic vaccines and systemic therapeutics modalities. Based on these learnings, we are excited to enter a new therapeutic area in autoimmune disease and announce two new development candidates, said Stphane Bancel, Modernas chief executive officer. We are entering 2020 with clear priorities, a strong cash balance and a talented team of employees focused on achieving our mission. With our CMV vaccine, we are preparing for our first pivotal Phase 3 study and we look forward to announcing additional new development candidates in our two clinically de-risked modalities, prophylactic vaccines and systemic therapeutics.
Mr. Bancel will present an update on the Company and its pipeline of mRNA development programs on Monday, January 13, 2020 at 4:30 p.m. PT at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will be followed by a question and answer session. A live webcast of both the presentation and question and answer session will be available under Events & Presentations in the investors section of Modernas website at investors.modernatx.com. A replay of the webcast will be archived on Modernas website for 30 days following the presentation.
Moderna currently has 21 mRNA development candidates in its portfolio with 13 in clinical studies. Across Modernas pipeline, more than 1,500 participants have been enrolled in clinical studies. The Companys updated pipeline can be found at http://www.modernatx.com/pipeline.
About Modernas New Autoimmune Therapeutic Area
Autoimmune diseases are characterized by immune activation in response to antigens normally present in the body, reflecting a loss of tolerance. Within this therapeutic area, the Company is developing two potential medicines, mRNA-6231 and mRNA-6981, designed to engage peripheral tolerance pathways to dampen autoimmune activation and help restore immune homeostasis, thereby reducing autoimmune pathology.
mRNA-6231 is an mRNA encoding for a long-acting IL-2 mutein designed to preferentially activate and expand the regulatory T cell population, dampening the immune response.
mRNA-6981 is an mRNA encoding for PD-L1 and is designed to augment cell surface levels of PD-L1 on myeloid cells, providing co-inhibitory signals to self-reactive lymphocytes.
As an initial step to addressing a range of autoimmune indications, the Company plans to conduct a Phase 1 study of mRNA-6231 in healthy adult volunteers and intends to pursue proof-of-concept with mRNA-6981 in a Phase 1 study in type 1 autoimmune hepatitis (AIH), a condition that involves liver inflammation and can lead to cirrhosis and liver failure. The Phase 1 study of mRNA-6231 will be the first clinical demonstration of subcutaneous administration of this delivery technology.
Both of these new autoimmune development candidates share the same delivery technology as mRNA-1944, the antibody against chikungunya, reducing technology risk. The autoimmune therapeutic area is Modernas fifth therapeutic area, in addition to infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases.
Program Updates by Modality:
Prophylactic vaccines: Moderna is developing vaccines against viral diseases where there is unmet medical need including complex vaccines with multiple antigens for common diseases, as well as vaccines against threats to global public health.
Serious infections transmitted from mother to baby
Serious respiratory infections
Global public health programs
Cancer Vaccines: These programs focus on stimulating a patients immune system with antigens derived from tumor-specific mutations to enable the immune system to elicit a more effective anti-tumor response.
Intratumoral Immuno-Oncology: These programs aim to drive anti-cancer T cell responses by injecting mRNA therapies directly into tumors.
Localized Regenerative Therapeutics: Localized production of proteins has the potential to be used as a regenerative medicine for damaged tissues.
Systemic Secreted & Cell Surface Therapeutics: In this modality, mRNA is delivered systemically to create proteins that are either secreted or expressed on the cell surface.
Systemic Intracellular Therapeutics: These programs aim to deliver mRNA into cells within target organs as a therapeutic approach for diseases caused by a missing or defective protein.
Information about each development candidate in Modernas pipeline, including those discussed in this press release, can be found on the investor relations page of its website: https://investors.modernatx.com/.
Corporate Objectives
Moderna continues to execute on its corporate objectives for 2019-2020, which include:
Corporate Updates
Key 2020 Investor and Analyst Event Dates
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the bodys cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Modernas platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. (NASDAQ: AZN) and Merck, Inc. (NASDAQ: MRK), as well as the Defense Advanced Research Projects Agency (NASDAQ: DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit http://www.modernatx.com.
1Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA) and The Bill and Melinda Gates Foundation (BMGF). Additional funding is subject to agreement on scope of additional projects.
SOURCE: Moderna Therapeutics
See the original post here:
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area | DNA RNA and...
Recommendation and review posted by G. Smith
